Pediococcus pentosaceus cqpfp202425 and application thereof

Abstract

The application provides a pentosus CQFP202425 and an application thereof, and belongs to the technical field of biological drugs. The pentosus CQFP202425 provided by the application has a preservation number of CGMCC No. 29781, is preserved in the China General Microbiological Culture Collection Center, and is located at No. 1, Beichen West Road, Chaoyang District, Beijing, China Academy of Microbiology Institute, on January 26, 2024. The pentosus CQFP202425 provided by the application can improve the accuracy of a 5-CRSTT task of a mouse, relieve the systemic inflammatory response of the mouse, increase the antioxidant level of the mouse, accelerate the generation of CAT, increase the level of SOD, repair the intestinal barrier, maintain the intestinal homeostasis, improve the expression of a neurotransmitter metabolism related path gene, maintain the homeostasis of the nervous system, and then regulate the concentration of the organism.

Description

Technical Field

[0001] This invention relates to the field of biopharmaceutical technology, and in particular to a species of Pediococcus pentosaceus, CQFP202425, and its applications. Background Technology

[0002] Attention, as a complex cognitive function, is key to high-level cognition. Its characteristics include filtering out distracting information, selecting correct information, and improving individual behavioral performance. Clear, accurate, controllable, and orderly behavior requires good attention. Attention deficits significantly impact daily life, and in severe cases, can lead to an inability to care for oneself. Attention deficits are often accompanied by hyperactivity and impulsivity. Mental illnesses characterized by cognitive deficits, such as schizophrenia, attention deficit hyperactivity disorder (ADHD), and bipolar disorder, are all related to attention to some extent. Therefore, research into attentional function and behavioral performance, as well as the neural circuits regulating attention, is crucial for understanding the characteristics and regulatory mechanisms of attentional performance.

[0003] Probiotics are a class of live microorganisms that benefit the host's health, playing a role in disease prevention or adjuvant therapy by producing beneficial substances and altering the composition of the host's gut microbiota. In recent years, various probiotics have been proven to possess multiple beneficial effects. Zhang et al. found that *Bifidobacterium animalis* subsp. lactis BL-99 exerts a therapeutic effect on functional dyspepsia by promoting the secretion of gastrin, which is regulated by short-chain fatty acids. C Chantarangkul et al. found that *Bifidobacterium animalis* MSMC83 reduces hyperlipidemia-related factors, such as cholesterol-7α-hydroxylase and antioxidant enzymes, in a rat model of hyperlipidemia, exerting lipid-lowering and antioxidant effects. Therefore, there is an urgent need to develop more probiotics that can prevent or treat attention deficit disorder. Summary of the Invention

[0004] In view of this, the purpose of this invention is to provide a Pediococcus pentosaceus CQFP202425 and its application. The Pediococcus pentosaceus CQFP202425 provided by this invention can effectively improve the expression of attention-related genes, improve the accuracy of the 5-CSRTT task, enhance concentration, and improve cognitive imbalance.

[0005] To achieve the above objectives, the present invention provides the following technical solution:

[0006] A type of Pediococcus pentosaceus ( Pediococcus pentosaceusThe Pediococcus pentosaceus CQFP202425, with accession number CGMCC No.29781, was deposited on January 26, 2024, at the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Beichen West Road, Chaoyang District, Beijing.

[0007] The present invention also provides a probiotic agent, comprising Pediococcus pentosaceus CQFP202425 as described in the above technical solution.

[0008] The present invention also provides the use of Pediococcus pentosaceus CQFP202425 or the probiotic agent described in the above technical solutions in the preparation of drugs for the prevention and / or treatment of attention disorders.

[0009] The present invention also provides the use of Pediococcus pentosaceus CQFP202425 or the probiotic agent described in the above technical solutions in the preparation of drugs for the prevention and / or treatment of cerebral edema.

[0010] The present invention also provides the use of Pediococcus pentosaceus CQFP202425 or the probiotic agent described in the above technical solutions in the preparation of drugs for the prevention and / or treatment of cognitive imbalance.

[0011] The present invention also provides the use of Pediococcus pentosaceus CQFP202425 or the probiotic agent described in the above technical solutions in the preparation of drugs for the prevention and / or treatment of oxidative stress.

[0012] The present invention also provides the use of Pediococcus pentosaceus CQFP202425 or the probiotic agent described in the above technical solutions in the preparation of drugs for the prevention and / or treatment of intestinal damage.

[0013] In some embodiments, the concentration of Pediococcus pentosaceus CQFP202425 in the drug is preferably 1 × 10⁻⁶. 9 CFU / mL.

[0014] In some embodiments, the drug is preferably, but not limited to, tablets, powders, capsules, or oral liquids.

[0015] In some embodiments, the medicament preferably also includes pharmaceutically acceptable excipients.

[0016] Beneficial technical effects: This invention provides a Pentosaccharidococcus ( Pediococcus pentosaceusPediococcus pentosaceus CQFP202425, with accession number CGMCC No. 29781, was deposited on January 26, 2024, at the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. The Pediococcus pentosaceus CQFP202425 provided by this invention can improve the accuracy of the 5-CSRTT task in mice, alleviate systemic inflammatory responses in mice, increase antioxidant levels in mice, accelerate CAT production, increase SOD levels, repair the intestinal barrier, maintain intestinal homeostasis, enhance the expression of genes related to neurotransmitter metabolism pathways, maintain nervous system homeostasis, and thus regulate the body's attention. Attached Figure Description

[0017] Figure 1 Plate morphology diagram of purified strain CQFP202425;

[0018] Figure 2 Gram staining results for purified strain CQFP202425;

[0019] Figure 3 Phylogenetic tree;

[0020] Figure 4 Changes in organ indices in mice; among them, Figure 4 A represents the mouse brain organ coefficient, and 4B represents the mouse liver organ coefficient; the same letter indicates no significant difference, and different letters indicate extremely significant differences. p <0.01;

[0021] Figure 5 These are the results of morphological observation of mouse brain tissue;

[0022] Figure 6 The accuracy rate of the 5-CSRTT training task in mice;

[0023] Figure 7 This represents the changes in 5-HT levels in mouse brain tissue; the same letter indicates no significant difference, and different letters indicate extremely significant differences. p <0.01;

[0024] Figure 8 This represents the changes in oxidative stress levels in mice; among which, Figure 8 A represents liver GSH, 8B represents liver CAT, 8C represents liver NO, 8D represents brain tissue GSH, 8E represents brain tissue CAT, and 8F represents brain tissue NO; the same letter indicates no significant difference, and different letters indicate extremely significant differences. p <0.01;

[0025] Figure 9 Changes in serum inflammation levels in mice; among them, Figure 9 A represents serum IL-6, 9B represents serum IL-10, and 9C represents serum IL-1β; the same letter indicates no significant difference, and different letters indicate extremely significant differences. p <0.01;

[0026] Figure 10 The changes in the relative expression levels of intestinal barrier genes in the mouse cecum; among which Figure 10 A is Claudin-1 Relative gene expression level, 10B ZO-1 Relative gene expression level, 10C Occludin-1 Relative gene expression levels; the same letter indicates no significant difference, different letters indicate significant differences. p <0.05. Detailed Implementation

[0027] To better understand the present invention, the following embodiments further illustrate the content of the present invention, but the content of the present invention is not limited to the following embodiments.

[0028] Unless otherwise specified, the experiments and methods described in the embodiments are performed in accordance with conventional methods well known in the art and described in various references. For example, conventional techniques such as immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA used in this invention can be found in Sambrook, Fritsch, and Maniatis, *Molecular Cloning: A Laboratory Manual*, 2nd edition (1989); *Current Protocols in Molecular Biology* (edited by FM. Ausubel et al., 1987); and the *Methods in Enzymology* series (academic publishing company): *PCR2: A Practical Approach* (M.J. MacPherson, B.D. .BD Hames and GR Taylor (eds. 1995), and ANIMAL CELLCULTURE (RI Freshney (ed. 1987)).

[0029] Furthermore, unless specific conditions are specified in the examples, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products. Those skilled in the art will understand that the examples are described by way of illustration and are not intended to limit the scope of protection claimed by the invention. All disclosures and other references herein are incorporated herein by reference in their entirety.

[0030] Example 1: Isolation, purification, and identification of bacterial strains

[0031] Pediococcus pentosaceus CQFP202425 was isolated from traditional homemade pickled vegetable fermentation broth in Chongqing. Single colonies were isolated using the dilution plate method. Each colony was selected and re-streaked, and the process was repeated 4-5 times to obtain the purified strain CQFP202425. Figure 1 ), to be stored for future use.

[0032] Bacterial species identification: Gram staining results of CQFP202425 are as follows Figure 2 As shown in the figure. The 16S rDNA sequence of CQFP202425 is shown in Seq_15. The results were compared by BLAST using NCBI, and the results are shown in Table 1. A phylogenetic tree was constructed using MEGA software. Figure 3 ).

[0033] Table 1 Results of 16S rDNA sequence analysis

[0034]

[0035] According to Table 1 and Figure 2 It is known that CQFP202425 is *Pediococcus pentosaceus*. The preservation information for this bacterium is as follows: Classification and nomenclature: *Pediococcus pentosaceus* Pediococcus pentosaceus The accession number is CGMCC No.29781. It was deposited on January 26, 2024 at the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Beichen West Road, Chaoyang District, Beijing.

[0036] In vitro resistance screening: Pediococcus pentosaceus CQFP202425 was subjected to artificial gastric juice and bile salt tests. The results are shown in Table 2.

[0037] Table 2 Results of in vitro resistance screening for Pediococcus pentosaceus

[0038]

[0039] Example 2 Animal Experiment

[0040] 2.1 Materials and Reagents

[0041] Place 1 mL of bacterial culture medium into a sterile centrifuge tube and centrifuge at 4000 rpm for 10 min, discarding the supernatant. Resuspend the bacterial pellet in sterile physiological saline and adjust the dose to 1 × 10⁻⁶. 9 The CFU / mL value is recorded as the bacterial culture group and reserved for gavage administration.

[0042] LPS, baicalin, Beijing Solarbio Biotechnology Co., Ltd.; Enzyme-linked immunosorbent assay kits for mouse interleukin (IL)-6, interleukin (IL)-1β, interleukin (IL)-10 and 5-hydroxytryptamine (5-HT) were purchased from Enzyme Immunosorbent Assay Co., Ltd.; Catalase (CAT), reduced glutathione (GSH), and vascular endothelial relaxing factor (NO) level detection kits were purchased from Nanjing Jiancheng Biotechnology Institute (Nanjing, China); Isopropanol, Tianjin Fuyu Fine Chemical Co., Ltd.; DEPC, Beijing Solarbio Biotechnology Co., Ltd.; Chloroform, Tianjin Fuyu Fine Chemical Co., Ltd.; Reverse transcription kit and Hief SYBR mix, Shanghai Yisheng Biotechnology Co., Ltd. (Shanghai, China).

[0043] 2.2 Instruments and Equipment

[0044] As shown in Table 3.

[0045] Table 3 Instruments and Equipment

[0046]

[0047] 2.3 Experimental Methods

[0048] According to reports (Guo LT, Wang SQ, Su J, Xu LX, Ji ZY, Zhang RY, Zhao QW, Ma ZQ, Deng XY, Ma SP. Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K / AKT / FoxO1 pathway. J Neuroinflammation. 2019 May 8;16(1):95. doi:10.1186 / s12974-019-1474-8. PMID: 31068207; PMCID: PMC6507025.), baicalin has a neuroprotective effect. In this invention, baicalin is used as a positive control.

[0049] 2.3.1 Animal Model

[0050] Twenty-four male C57BL mice were purchased from Hunan Slack Jingda Experimental Animal Co., Ltd. The production license number of experimental animals is SCXK (Xiang) 2019-0004, and they were raised in the Children's Nutrition and Collaborative Innovation Center of Chongqing University of Education. The ethical license number for animal experiments is 2024112507B. After the adaptive feeding period, they were randomly divided into 4 groups of 6 mice each, namely: normal group (Control), model group (Model), baicalin group (Baicalin), and bacterial solution group (CQFP202425: Pediococcus pentosaceus CQFP202425 at 1×10 9 CFU / mL). The specific treatment measures for each group were as follows: The Control group was not treated; the Model group was gavaged with normal saline for 14 days, and starting from the 10th day, sterile LPS solution (0.83 mg / kg) was intraperitoneally injected continuously for 3 days; the Baicalin group was gavaged with baicalin (60 mg / kg) for 14 days, and starting from the 10th day, sterile LPS solution was intraperitoneally injected continuously for 3 days; the bacterial solution group was gavaged with Pediococcus pentosaceus CQFP202425 bacterial solution for 14 days, and starting from the 10th day, sterile LPS solution was intraperitoneally injected continuously for 3 days; the gavage and injection doses were both 0.1 mL / 10 g.

[0051] Collection of mouse serum: At the end of the experiment, the mice that had fasted for 12 h were anesthetized, their whiskers were cut off, and then their eyeballs were quickly removed, and the blood was collected in endotoxin-free tubes. After grouping and labeling, the serum samples were left to stand at 37 °C for 30 min, centrifuged at 4 °C and 3000 r / min for 10 min, and the supernatant was frozen at -80 °C for subsequent detection, avoiding repeated freezing and thawing.

[0052] Collection of mouse organ tissues: After collecting the serum, the mice were quickly dissected, and the whole brain, liver, and cecum of the mice were taken out, rinsed in pre-cooled physiological saline to remove the serum and mucosa adhering to them, and the surface moisture was quickly blotted dry with filter paper. The whole brain tissue was cut into pieces and divided into three parts. One part was immersed in a 4% (v / v) paraformaldehyde solution (prepared in PBS) with a volume 20 times that of the tissue for tissue observation; another part was added to 9 times the pre-cooled 0.9% physiological saline and quickly ground in an electric homogenizer, centrifuged at 4 °C and 8000 r / min for 15 min, and the supernatant was frozen at -80 °C for ELISA (enzyme-linked immunosorbent assay) kit detection, avoiding repeated freezing and thawing; the third part was quickly frozen in liquid nitrogen in tin foil and quickly transferred to a sterile 1.5 mL ep tube and frozen at -80 °C for fluorescence quantitative detection. The liver tissue was weighed and frozen at -80 °C for subsequent detection. The cecum tissue was wrapped in tin foil and quickly frozen in liquid nitrogen, and quickly transferred to a sterile 1.5 mL ep tube and frozen at -80 °C for fluorescence quantitative detection.

[0053] 2.3.2 Training and testing of 5-CSRTT in mice

[0054] (1) Water restriction stage

[0055] After a week of acclimatization, the mice were placed in a restricted water period for eight consecutive days, with water provided at intervals of 4 hours, 3.5 hours, 3 hours, 2.5 hours, 2 hours, 1.5 hours, 1 hour, and 0.5 hours. Their weight was measured at 10:00 AM each day. If the mouse's weight was below 90% of its previous weight, the water restriction was considered to have achieved the desired result. If it was below 80% of its previous weight, the mouse's health should be monitored to prevent dehydration leading to decreased mobility or even death. After the water restriction period ended, behavioral training was initiated, followed by 15 minutes of water replenishment after each daily behavioral training session.

[0056] (2) Adaptive training phase

[0057] Mice that meet the health criteria enter the adaptive training phase, which consists of four stages. In the first stage, the 5-choice Habituation 1 program is run (10 minutes). During this stage, mice are free to explore the control box; the screen and light in the control box are not lit, and no sugar water reward is provided. In the second stage, 5-choice Habituation 2 is run (30 minutes, 100 trials). In this stage, the five-hole screen light is off, but the food trough light is on. When the mouse touches the trough light, it receives a liquid reward (2% sucrose). Through repeated touching of the trough light, the mouse establishes a connection between the trough light and the sugar water reward. One round of the experiment ends when the mouse completes 100 trials or the cumulative experimental time reaches 30 minutes. If the number of times the reward is received is greater than 50, the mouse enters the third stage; otherwise, the second stage is repeated until the target is met.

[0058] The third stage involves running the 5-choice Touch Training program (30 minutes, 100 trials). Five screens (4cm x 4cm) are randomly lit. When the mouse touches a screen, a light in the control box illuminates. Upon touching a lit light, sugar water is pumped out of the box as a reward. The five screens are then randomly lit again (without interval) to proceed to the next trial. Mice that receive rewards ≥50 times proceed to the fourth stage, running the 5-choice Touch Training 4 program (30 minutes, 100 trials). This stage is essentially the same as the third stage, except that there is a 5-second interval after each reward. When the mouse achieves more than 50 correct attempts, it enters the training stage.

[0059] 2.3.3 Detection of 5-HT levels in mouse brain tissue, oxidative stress levels in mouse brain and liver tissue, and serum inflammation levels.

[0060] Mouse liver and brain tissue homogenates were collected separately, and oxidative stress levels were detected using catalase (CAT), reduced glutathione (GSH), and vascular endothelial relaxing factor (NO) kits. At the same time, the serum levels of IL-6, IL-10, and IL-1β, as well as the 5-HT content in the brain tissue homogenate, were measured using ELISA kits. The experimental procedures were performed in accordance with the kit instructions.

[0061] 2.3.4 Morphological observation of mouse brain tissue

[0062] Brain tissue, fixed with fixative, was harvested in 4 mm thickness using the coronal method. It was then dehydrated in a gradient manner using 70%, 80%, 95%, and 100% ethanol, with each dehydration process lasting 30 min. After dehydration, the tissue was soaked in xylene for 20 min each, followed by paraffin embedding for 30 min. The tissue was then cut into 4 μm sections using a microtome. The sections were gently mounted on glass slides and dried in an oven before staining with hematoxylin and eosin (HE). Histological characteristics were then observed and analyzed under an optical microscope after staining.

[0063] 2.3.5 Detection of the relative expression levels of CREB, ERK1 / 2, BDNF in mouse brain tissue and intestinal barrier genes zo-1, occludin-1, and claudin-1 in the cecum

[0064] RNA was extracted from brain and cecal tissues frozen at -80℃ using the Trizol method. After purity testing, the RNA was frozen at -80℃ for later use. The extracted RNA was reverse transcribed using the ReverTra Ace® qPCR RT Master Mix kit, following the instructions for use at ice temperature. The transcription was performed at 65℃ (5 min) → 42℃ (60 min) → 70℃ (5 min) → 4℃ (hold) to obtain cDNA from the corresponding tissues. The template cDNA and primers were mixed using the TOYOBO SYBR® Green Realtime PCR Master Mix kit, and fluorescent dye and high-fidelity enzyme were added according to the kit instructions. PCR amplification was performed under 40 cycles of 95℃ for 5 min; 94℃ for 30 s; 60℃ for 40 s; 72℃ for 1 min. Real-time quantitative PCR analysis was performed using β-actin as an internal reference gene. Primer sequences are shown in Table 4. The CT value method (2) was used for calculation. -ΔΔCT ).

[0065] Table 4 Primers and their sequences used in RT-qPCR

[0066]

[0067] 2.3.6 Data Processing

[0068] The data were analyzed using one-way ANOVA based on the Turkey test. p A value < 0.05 was considered significant; graphs were plotted using GraphPad Prism 8.0 software (GraphPad Software, San Diego, CA, USA).

[0069] 2.4 Results and Analysis

[0070] 2.4.1 Organ coefficient of mouse brain tissue

[0071] Organ index represents the movement and physiological function of organs under constant conditions and is an important indicator for toxicological evaluation in mice. An elevated organ index may be due to organ congestion and edema, while a low organ index may be due to muscle atrophy or toxic effects on the body. This study calculated the organ index by weighing mouse brain and liver tissues, and the results are as follows: Figure 4 As shown, the brain tissue and liver organ indices of the Model group mice were significantly higher than those of the Control group ( p <0.01 indicates that LPS treatment caused congestion and edema in the brain and liver of mice, affecting the normal physiological functions of the body; treatment with baicalin caused a decrease in organ indices; after treatment with Pediococcus pentosaceus CQFP202425, the organ indices of the brain and liver were significantly lower than those of the Model group ( p The value was <0.01, and there was no significant difference compared with the Control group, indicating that Pediococcus pentosaceus CQFP202425 helps regulate LPS-induced brain congestion and edema in mice and restore normal physiological functions.

[0072] 2.4.2 Pathological observation of mouse brain tissue

[0073] like Figure 5 As shown, the brain tissue structure of the Control group was intact, with densely packed cells. Two inflammatory lesions were observed on the surface of the brain in the Model group, and the gaps between neurons near the lesions and surrounding tissues increased, indicating that LPS caused edema in the brain tissue. Overall, the nerve cells in the tissue were densely stained, and the nuclei were indistinct, indicating that LPS caused cellular shrinkage in the brain tissue, affecting its normal physiological morphology. In the bacterial culture-treated group, some neurons in the cerebral cortex of mice showed degeneration, but no obvious inflammatory cell infiltration was observed. Therefore, Pediococcus pentosaceus CQFP202425 has a certain protective effect against LPS-induced brain tissue in mice.

[0074] 2.4.3 Exponential changes in 5-CSRTT in mice

[0075] Mice in each group were trained on the 5-CSRTT task separately. The task accuracy of the mice within the same time period (15 min) was as follows: Figure 6 As shown in Table 5. From Figure 3 As shown in Table 5, after LPS gavage modeling, the task accuracy of mice in the model group decreased by 57.91%, and the other treatment groups also showed a decrease. The task accuracy of mice in the Baicalin group decreased by 52.77%, which was a slight improvement compared to the model group. The task accuracy of mice in the CQPF202425 group decreased by 55.27%, indicating that Pediococcus pentosaceus CQFP202425 can improve LPS-induced cognitive imbalance.

[0076] Table 5. Accuracy of 5-CSRTT training task in mice

[0077]

[0078] 2.4.4 Changes in 5-HT levels in mouse brain tissue

[0079] The levels of 5-HT in the brain tissue of mice in each group were as follows: Figure 7 As shown. By Figure 7 It can be seen that LPS treatment leads to a significantly higher level of 5-HT in the mouse brain compared to the control group. p The level <0.01 indicates that LPS leads to serotonin accumulation in the brain, causing neurotransmitter imbalance and affecting normal physiological functions. After treatment with Pediococcus pentosaceus CQFP202425, the 5-HT level in the brain tissue decreased to some extent, indicating that Pediococcus pentosaceus CQFP202425 can regulate LPS-induced neurotransmitter imbalance, maintain nervous system homeostasis, and thus regulate attention and cognitive imbalance.

[0080] 2.4.5 Changes in oxidative stress levels in mice

[0081] The levels of GSH, CAT, and NO in the brain tissue and liver of mice in each group are as follows: Figure 8 As shown. By Figure 8 It can be seen that LPS treatment resulted in significantly lower levels of GSH and CAT in the mouse brain compared to the control group. p The value <0.01 indicates that LPS induces oxidative stress in the body, affecting normal physiological functions. After treatment with *Pediococcus pentosaceus* CQFP202425, the body's oxidative stress level rebounded to some extent, significantly higher than the model group. Furthermore, the GSH and NO levels in the bacterial culture group did not differ significantly from those in the control group. This suggests that *Pediococcus pentosaceus* CQFP202425 can regulate LPS-induced abnormal oxidative stress levels in the body.

[0082] 2.4.6 Changes in serum inflammation levels in mice

[0083] Serum inflammation levels in each group of mice were as follows: Figure 9 As shown. By Figure 9 It can be seen that LPS treatment resulted in significantly higher levels of IL-6, IL-10, and IL-1β in the mouse brain compared to the control group. p <0.05, p <0.01 indicates that LPS leads to a significant increase in the level of inflammatory factors in the body, thereby causing an inflammatory response and affecting the body's normal physiological functions. After treatment with Pediococcus pentosaceus CQFP202425, although the levels of some inflammatory factors were still higher than those in the normal group, they were significantly lower than those in the Model group ( p <0.01). This indicates that LPS treatment increases the level of inflammatory factors in mice, which may lead to inflammation and affect normal physiological and biochemical states. However, intervention with Pediococcus pentosaceus CQFP202425 slows down the rise in inflammatory factor levels and alleviates the inflammatory response.

[0084] 2.4.7 Changes in the relative expression levels of genes in the BDNF metabolic pathway in the mouse brain

[0085] The changes in the relative expression levels of genes in the BDNF metabolic pathway in the brains of mice in each group are shown in Table 6. As shown in Table 6, LPS treatment resulted in significantly lower relative expression levels of key genes in the BDNF metabolic pathway, BDNF and ERK1 / 2, in the mouse brain compared to the Control group. p <0.05 indicates that LPS leads to a decrease in the expression of genes related to the BDNF metabolic pathway in the brain, resulting in neurotransmitter imbalance and affecting the maintenance of normal nervous system function in mice. After treatment with Pediococcus pentosaceus CQFP202425, the relative expression levels of the three key genes were significantly increased, all significantly higher than those in the model group ( p <0.05).

[0086] Table 6. Changes in the relative expression levels of genes in the BDNF metabolic pathway in the mouse brain.

[0087]

[0088] Note: Same letters indicate no significant difference, different letters indicate a significant difference. p <0.05

[0089] 2.4.8 Changes in the relative expression levels of intestinal barrier genes in the mouse cecum

[0090] The changes in the relative expression levels of intestinal barrier genes in the cecum of mice in each group are as follows: Figure 8 As shown. By Figure 8It is known that LPS treatment downregulates the expression of intestinal barrier genes in the mouse cecum, disrupting the intestinal barrier and leading to physiological imbalance. After treatment with Pediococcus pentosus CQFP202425, the relative expression levels of the three barrier gene mRNAs were significantly increased, all significantly higher than those in the model group. p The result was <0.05, indicating that Pediococcus pentosaceus CQFP202425 can alleviate the damaging effect of LPS on the intestinal barrier.

[0091] In conclusion, Pediococcus pentosaceus CQFP202425 can alleviate inflammation, regulate oxidative stress, and modulate focus by influencing neurotransmitter expression.

[0092] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A type of Pediococcus pentosaceus ( Pediococcus pentosaceus CQFP202425, characterized in that, The Pediococcus pentosaceus CQFP202425 has the accession number CGMCC No.29781 and was deposited on January 26, 2024, at the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. The Pediococcus pentosaceus CQFP202425 was isolated from the fermentation liquid of traditional homemade pickled vegetables in Chongqing.

2. A probiotic agent, characterized in that, Includes Pediococcus pentosaceus CQFP202425 as described in claim 1.

Images